Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 140, Issue 2, 2008, Pages 258-262

  Rauber, D ^a   Mehlhorn, G ^a   Fasching, P A ^a   Beckmann, M W ^a   Ackermann, S ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Darmstadt Hospital   (Germany)

Author keywords

Antibodies; Capsids; Cervical dysplasia; Human papillomavirus; Immunohistochemistry; Prognosis

Indexed keywords

PROTEIN PAPILLOMA VIRUS L1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

EID: 52949098709     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.05.003     Document Type: Article

References (32)

1. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
2. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
3. von Knebel D.M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38 (2002) 2229-2242
4. Kruse A.J., Baak J.P., Janssen E.A., et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 26 (2004) 13-20
5. Baak J.P., and Kruse A.J. Use of biomarkers in the evaluation of CIN grade and progression of early CIN. Methods Mol Med 119 (2005) 85-99
6. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006) 489-498
7. Baak J.P., Kruse A.J., Janssen E., and van Diermen B. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol 27 (2005) 357
8. Ciavattini A., Lucarini G., Castaldini C., et al. bcl-2 protein expression in cervical intraepithelial neoplasia: no evidence of a prognostic significance in mild and moderate lesions. Anticancer Res 19 (1999) 5463-5467
9. Dellas A., Schultheiss E., Leivas M.R., Moch H., and Torhorst J. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. Anticancer Res 18 (1998) 3991-3998
10. Garzetti G.G., Ciavattini A., De Nictolis M., et al. MIB 1 immunostaining in cervical intraepithelial neoplasia: prognostic significance in mild and moderate lesions. Gynecol Obstet Invest 42 (1996) 261-266
11. Herbsleb M., Knudsen U.B., Orntoft T.F., et al. Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 109 (2001) 607-617
12. Hering B., Horn L.C., Nenning H., and Kuhndel K. Predictive value of DNA cytometry in CIN 1 and 2. Image analysis of 193 cases. Anal Quant Cytol Histol 22 (2000) 333-337
13. Kruse A.J., Baak J.P., de Bruin P.C., et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol 193 (2001) 48-54
14. Pirog E.C., Baergen R.N., Soslow R.A., et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol 26 (2002) 70-75
15. von Knebel D.M. New molecular tools for efficient screening of cervical cancer. Dis Markers 17 (2001) 123-128
16. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110 (2006) 525-541
17. Melsheimer P., Kaul S., Dobeck S., and Bastert G. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 47 (2003) 124-128
18. Birner P., Bachtiary B., Dreier B., et al. Signal-amplified colorimetric in situ hybridization for assessment of human papillomavirus infection in cervical lesions. Mod Pathol 14 (2001) 702-709
19. Baak J.P., Kruse A.J., Janssen E., and van Diermen B. Predictive testing of early CIN behaviour by molecular biomarkers. Cell Oncol 27 (2005) 277-280
20. Kruse A.J., Skaland I., Janssen E.A., et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 23 (2004) 100-109
21. Wang J.L., Zheng B.Y., Li X.D., et al. p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia. Mod Pathol 18 (2005) 629-637
22. Wang J.L., Zheng B.Y., Li X.D., Angstrom T., Lindstrom M.S., and Wallin K.L. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 10 April (2004) 2407-2414
23. Kurvinen K., Syrjanen K., and Syrjanen S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. J Clin Oncol 14 (1996) 2120-2130
24. Turan T., Kalantari M., Calleja-Macias I.E., et al. Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?. Virology 349 (2006) 175-183
25. Turan T., Kalantari M., Cuschieri K., Cubie H.A., Skomedal H., and Bernard H.U. High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 361 (2007) 185-193
26. Klaes R., Woerner S.M., Ridder R., et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59 (1999) 6132-6136
27. Kulmala S.M., Syrjanen S.M., Gyllenstein U.B., et al. Early integration of high-copy HPV 16 detectable in women with normal and low-grade cervical cytology and histology. J Clin Pathol (2006)
28. Peitsaro P., Johansson B., and Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40 (2002) 886-891
29. Griesser H., Sander H., Hilfrich R., Moser B., and Schenck U. Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol 26 (2004) 241-245
30. Clavel C., Masure M., Bory J.P., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 84 (2001) 1616-1623
31. Woodman C.B., Byrne P., Kelly K.A., and Hilton C. A randomized trial of laser vaporization in the management of cervical intraepithelial neoplasia associated with human papilloma virus infection. J Public Health Med 15 (1993) 327-331
32. Winer R.L., Kiviat N.B., Hughes J.P., et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 191 (2005) 731-738